Compare ACHV & BOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACHV | BOT |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Puerto Rico |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 618.0M | 627.1M |
| IPO Year | 2018 | 2025 |
| Metric | ACHV | BOT |
|---|---|---|
| Price | $7.59 | $31.67 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $14.67 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 445.9K |
| Earning Date | 05-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.55 | $23.60 |
| 52 Week High | $7.34 | $43.72 |
| Indicator | ACHV | BOT |
|---|---|---|
| Relative Strength Index (RSI) | 73.79 | 54.74 |
| Support Level | $4.04 | $30.34 |
| Resistance Level | N/A | $37.20 |
| Average True Range (ATR) | 0.33 | 3.10 |
| MACD | 0.08 | 0.59 |
| Stochastic Oscillator | 98.71 | 72.91 |
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
RoboStrategy Inc is a closed-end, non-diversified management investment company. The Fund's investment objective is to seek long-term capital appreciation, principally through capital gains on equity and equity-linked investments in robotics and embodied AI companies. The Fund focuses on private, venture-capital-backed companies with growth potential, many of which are not yet publicly listed or widely accessible to individual investors.